Inovio Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for its new immunotherapy, VOCERYQ. This treatment is designed to reduce the frequency of surgeries required for adults suffering from Recurrent Respiratory Papillomatosis (RRP), a rare and debilitating disease. The approval represents a significant advancement for Inovio as it expands its portfolio of innovative therapies.

VOCERYQ, previously known as INO-3107, is a plasmid DNA-based immunotherapy that targets the human papillomavirus types 6 and 11, which are the root causes of RRP. The FDA's accelerated approval is based on the promising results from clinical trials demonstrating that the treatment can lead to a complete response, defined as no surgical intervention required for 12 months after treatment.

Background

Inovio Pharmaceuticals, Inc. operates in the pharmaceutical preparations sector, specifically focusing on developing and commercializing DNA medicines for HPV-related diseases, cancer, and infectious diseases. The company trades under the ticker symbol INO on the Nasdaq exchange. Inovio has a history of innovation in the biotechnology space, with recent filings indicating ongoing efforts to advance its product offerings.

What the Filing Says

According to the recent SEC filing, Inovio announced, "the FDA has granted accelerated approval for VOCERYQ to reduce the frequency of surgery in adults with RRP." The company also stated that continued approval may depend on further confirmatory studies to verify the clinical benefits of the treatment.

Impact

The approval of VOCERYQ is expected to significantly impact patients with RRP, who often face multiple surgeries to manage their condition. The treatment offers a new, non-surgical option that could improve the quality of life for these individuals. Additionally, this milestone positions Inovio as a leader in the development of innovative therapies within the pharmaceutical industry.

What's Next

Inovio plans to make VOCERYQ available for order and shipment in approximately 60 days, with a full commercial launch anticipated in the first quarter of 2027. The company will also conduct a confirmatory study as required by the FDA to further validate the treatment's clinical benefits.